BRIEF-Beigene Provides Update On Phase 2 Clinical Trial Of Zanubrutinib In Patients With Covid-19-Related Pulmonary Distress
BRIEF-Beigene Provides Update On Phase 2 Clinical Trial Of Zanubrutinib In Patients With Covid-19-Related Pulmonary Distress
Brief-BEI基因提供扎努布鲁替尼治疗新冠肺炎相关性肺窘迫患者第二期临床试验的最新进展
April 8 (Reuters) - Beigene Ltd 6160.HK :
路透4月8日电-贝基恩有限公司6160.HK:
* BEIGENE PROVIDES UPDATE ON PHASE 2 CLINICAL TRIAL OF ZANUBRUTINIB IN PATIENTS WITH COVID-19-RELATED PULMONARY DISTRESS
*BEYGEN提供ZANUBRUTINIB治疗新冠肺炎相关性肺窘迫患者的2期临床试验的最新情况
* BEIGENE LTD - TRIAL DID NOT MEET CO-PRIMARY EFFICACY ENDPOINTS; NO NEW SAFETY SIGNALS IDENTIFIED
*BEYGEN LTD-试验未达到联合主要疗效终点;没有发现新的安全信号
* BEIGENE LTD - THERE WERE NO NEW OR ADDITIONAL SAFETY SIGNALS FOR ZANUBRUTINIB IDENTIFIED IN TRIAL
*BEYGEN LTD-在试验中没有发现ZANUBRUTINIB新的或额外的安全信号
Source text for Eikon: Further company coverage:
Eikon的源文本:进一步的公司报道:
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。